Sofia Tzamarelou: Georgi Ivanov wrote a fantastic piece on ASCO 2024
Sofia Tzamarelou, Senior Consultant at Commetric, shared on LinkedIn:
“Our very own Georgi Ivanov wrote a fantastic piece on ASCO 2024.
Click on the link to access the article and the accompanying report.
Key take-aways included:
Shift Towards Less Invasive Treatments:
ASCO 2024 highlighted a shift towards less invasive cancer treatments, showing that reduced surgery, chemotherapy, and radiation can help patients live longer and feel better.
Studies from Takeda, AstraZeneca, Daiichi Sankyo, and Merck demonstrated the effectiveness of this approach across various cancers.
Media Focus and Innovation Highlights:
The meeting generated media attention with key stories like Pfizer‘s Lorbrena and AstraZeneca’s Tagrisso, which showed significant reductions in lung cancer progression.
Despite these innovations, the media’s primary focus was on the broader narrative of less invasive treatments.
PR and Communication Implications:
The media’s emphasis on less intensive treatments suggests a shift in oncology communications towards improving patient outcomes with less aggressive therapies.
This new perspective may become central in future oncology PR strategies.”
Source: Sofia Tzamarelou/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023